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Background
Lewy body dementia, consisting of both dementia with Lewy
bodies (DLB) and Parkinson’s disease dementia (PDD), is
considerably under-recognised clinically compared with its
frequency in autopsy series.
Aims
This study investigated the clinical diagnostic pathways of
patients with Lewy body dementia to assess if difficulties in
diagnosis may be contributing to these differences.
Method
We reviewed the medical notes of 74 people with DLB and 72
with non-DLB dementia matched for age, gender and cognitive
performance, together with 38 people with PDD and 35 with
Parkinson’s disease, matched for age and gender, from two
geographically distinct UK regions.
Results
The cases of individuals with DLB took longer to reach a final
diagnosis (1.2 v. 0.6 years, P = 0.017), underwent more scans
(1.7 v. 1.2, P = 0.002) and had more alternative prior diagnoses
(0.8 v. 0.4, P = 0.002), than the cases of those with non-DLB
dementia. Individuals diagnosed in one region of the UK had
significantly more core features (2.1 v. 1.5, P = 0.007) than those
in the other region, and were less likely to have dopamine
transporter imaging (P < 0.001). For patients with PDD, more than
1.4 years prior to receiving a dementia diagnosis: 46% (12 of 26)
had documented impaired activities of daily living because of
cognitive impairment, 57% (16 of 28) had cognitive impairment in
multiple domains, with 38% (6 of 16) having both, and 39% (9 of
23) already receiving anti-dementia drugs.
Conclusions
Our results show the pathway to diagnosis of DLB is longer and
more complex than for non-DLB dementia. There were also
marked differences between regions in the thresholds clinicians
adopt for diagnosing DLB and also in the use of dopamine
transporter imaging. For PDD, a diagnosis of dementia was
delayed well beyond symptom onset and even treatment.
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Lewy body dementia, consisting of dementia with Lewy bodies
(DLB) and Parkinson’s disease dementia (PDD), is the second
most common neurodegenerative dementia in older people, and
comprises 15–20% of cases of dementia in pathological studies.1,2
However, clinically the prevalence is much lower, with DLB preva-
lence reported to be 4.2–5%3,4 of all patients with dementia and
PDD prevalence is reported to be 3.6%.5 In this study we analysed
the diagnostic pathways of patients with DLB and PDD, to under-
stand if difficulties in diagnosis contribute to the divergence in
LBD prevalence between clinical and pathological samples.
Method
An initial survey of the prevalence in secondary care clinical services
of patients diagnosed with DLB and those with PDDwas carried out
in two geographical areas of UK – East Anglia and the North East of
England (the ‘North East’) – and has been previously reported.6 The
regions and underlying services were chosen by the research team in
order to compile a cohort generalisable to that seen in routine clin-
ical practice and included those serving both urban populations and
mixed urban and rural populations. For assessing DLB, the survey
investigated the frequency of the diagnosis as a proportion of all
patients with dementia in nine old-age psychiatry/memory clinic
services across four National Health Service (NHS) hospital trusts.
The majority (seven) of the services were secondary care organisa-
tions, whereas the remaining two consisted of a tertiary memory
clinic combining psychiatry and neurology expertise in East
Anglia, as well as a tertiary DLB clinic in the North East, reviewing
individuals diagnosed with DLB from a secondary care centre.
For assessing the proportion of PDD diagnosis in people with
Parkinson’s disease, five Parkinson’s disease or movement disorder
clinics, each from a separate NHS trust (three in East Anglia, two in
the North East) were sampled. These consisted of three combined
geriatric medicine and neurology services and two geriatric medi-
cine only services, serving two urban and three mixed urban and
rural populations. None of these services incorporated specialist ter-
tiary clinics.
For DLB, all new cases of patients referred to and assessed
within selected services in an 18-month period during 2013 and
2014, were surveyed for diagnoses made. This entailed a brief
review of the medical records of each patient from that service to
detect if dementia was diagnosed. If so, further demographic and
diagnostic details were recorded. Patients were considered to have
a DLB diagnosis if their last diagnosis in the medical records in
the screening period was either ‘probable’ or ‘possible’ DLB or
mixed dementia with DLB specifically mentioned. The study was
carried out prior to the publication of the 2017 consensus criteria
for DLB,7 hence the medical notes reflected the use by clinicians
of the earlier 2005 criteria8 and we have therefore referred to the
2005 criteria in the analysis of the results.
For PDD, all patients seen in the stated services in an 18-month
period within 2014 and 2015, aged 65 and over, were surveyed for
whether a Parkinson’s disease diagnosis was made. Demographic
and diagnostic details were then collected for such patients.
Patients were recorded as having PDDwhere the records specifically
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stated ‘dementia’ as a diagnosis. The term ‘cognitive impairment’ or
similar terms were not sufficient. The 2007 Movement Disorder
Society (MDS) criteria9,10 were the relevant criteria deemed to
have been applied by clinicians in the diagnosis of PDD.
Medical notes review
Patients identified in the initial prevalence survey as diagnosed with
DLB or, in the case of the PDD survey, PDD, were approached for
written consent to carry out a detailed analysis of their diagnostic
pathway, except if (a) it was deemed the approach was unsuitable
on clinical grounds, (b) they could not be contacted, or (c) they
had died.
Once consent was obtained, a matched comparison/control
patient was identified for that participant from the next consecutive
patient with non-DLB dementia or non-dementia Parkinson’s
disease (as appropriate) seen in the same service who satisfied the
matching criteria (below) and they were approached for written
consent. Patients with DLB were matched according to gender,
age at dementia diagnosis (+/– 5 years) and Mini-Mental State
Examination (MMSE)11 score at time of diagnosis (with severe:
0–9; moderate: 10–20; or mild: ≥21).
Patients with PDD were matched according to age at referral for
Parkinson’s disease symptoms (+/– 5 years) and gender. If the next
such potential comparison patient declined or was not suitable, the
following patient that matched criteria was identified, and so on
until a comparison patient was recruited.
For patients with DLB, a PDD diagnosis (in accordance with the
2007 MDS criteria) was an exclusion criterion in the recruitment of
control participants. For the Parkinson’s disease (non-dementia)
comparison patients, treatment with anti-dementia drugs during
the 18-month survey period was an exclusion criterion, since pre-
scription of these drugs would suggest significant cognitive impair-
ment and possible de facto dementia despite dementia not being
formally diagnosed by the clinician in the medical records, hence
such participants would not be suitable control patients.
Recruitment
With respect to the patients with DLB, 207 were identified in the
prevalence study. Of these, 102 were not approached: 54 had died
before we could approach, 6 were deemed unsuitable for approach
by the research team (for example they had already stated that they
were not interested in participating in research), 24 were deemed
unsuitable for approach by the clinical team and 18 were not con-
tactable. Of the 105 that were approached, 30 declined. One
further patient was excluded following review of the diagnosis by
the expert panel, leaving 74 participants in the analysis (the DLB
group).
For the patients with PDD, 161 were identified in the prevalence
study. From this group, 108 were not approached, this included: 12
who had died, 3 deemed unsuitable for approach by the research
team, 15 deemed unsuitable for approach by the clinical team, 4
who were not contactable and 74 who were not considered for
approach. Of the 53 remaining, 15 declined participation, leaving
38 recruited patients (the PDD group).
One DLB participant could not be matched despite an extensive
search, leaving 73 matched comparison participants (the non-DLB
group). Of the 38 patients with PDD recruited, 3 were similarly
unmatched, leaving 35 comparison patients (the Parkinson’s
disease group).
Once written informed consent was obtained, a case report form
was completed for each participant based on the patient’s medical
records, collating the details of their diagnostic and management
pathway including clinical features, investigations, clinical appoint-
ments and medications prescribed from the time of their initial
referral for their symptoms to the end of the 18-month screening
period. A panel of expert clinicians subsequently reviewed each
case report form to verify the diagnosis. The 2005 consensus cri-
teria8 for DLB and the 2007 MDS criteria9,10 for PDD were
applied as appropriate to each participant, including the control
participants with the aim of excluding participants from the analysis
if the LBD diagnosis were incorrect in the participants in the two
LBD groups (i.e. DLB and PDD groups) or if participants with
LBD were identified in the two control groups (i.e. non-DLB and
Parkinson’s disease groups).8–10
One matched comparison patient for the DLB group, diagnosed
by the clinical team with Alzheimer’s disease was subsequently
excluded as they were deemed by the expert panel to have PDD,
hence leaving 72 control patients in that group. The experts
achieved consensus and agreed with all other diagnoses.
Statistical analysis
Data were analysed using the Statistical Package for Social Sciences
software version 25 (SPSS; IBM Corporation, USA). Differences in
demographic and clinical data were assessed using either t-tests,
analysis of variance (ANOVA), or rank-sum tests (Mann–
Whitney U) as appropriate for continuous variables and χ2-test
for categorical data. Pearson’s correlation was used to assess linear
associations for continuous variables. For each test statistic, a prob-
ability value (P) of <0.05 was regarded as significant.
Ethical approval
The authors assert that all procedures contributing to this work
comply with the ethical standards of the relevant national and insti-
tutional committees on human experimentation and with the
Helsinki Declaration of 1975, as revised in 2008. All procedures
involving human patients were approved by regional NHS
Research Ethics Committee (NRES Committee North East—
Newcastle & North Tyneside 1; Reference 13/NE/0268).
Results
Demographics
Patients and controls were well matched for age at time of referral
and gender (see Table 1), as would be expected from the matching
process used. The non-DLB group consisted of 48 participants with
Alzheimer’s disease, 7 with vascular and 17 withmixed (Alzheimer’s
disease and vascular) dementia.
Comparison of diagnostic pathways in DLB
A comparison of the diagnostic pathways of the DLB and non-DLB
dementia groups was carried out (see Table 2). Before a final diag-
nosis was made, those in the DLB group received significantly
more alternate diagnoses, clinical assessments at home and
imaging tests (including dopaminergic 123I-N-ω-fluoropropyl-
2beta-carbomethoxy-3beta-4-iodophenyl nortropane (123I-FP-CIT)
brain single-photon emission computerised tomography (SPECT)
(FP-CIT) imaging) than those in the non-DLB group.
When ‘mild cognitive impairment’ (MCI), which accounted for
about a fifth of these alternate initial diagnoses across both groups,
was removed the differences were even greater with a mean of 0.65
alternate prior diagnoses for the DLB group compared with 0.17 for
the non-DLB group (t = 4.27, P < 0.001).
In addition, the proportion of the DLB group receiving an alter-
nate diagnosis prior to their final diagnosis was higher than in the
non-DLB group (51% (38/74) v. 31% (22/72), χ2 = 6.5, P = 0.01).
Removing MCI diagnoses from both groups again led to even
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greater differences, with 46% (34/74) of the DLB group but only
13% (9/72) of the non-DLB group receiving an alternate prior diag-
nosis (χ2 = 19.6, P < 0.001). The DLB group also had a significantly
longer time period, on average 1.2 years compared with 0.6 years,
between their first appointment in secondary care and the date of
their final diagnosis.
The mean time between the date of final diagnosis and initiation
of treatment for dementia (such as donepezil) was also significantly
different between groups. Treatment on average was started before a
final diagnosis in the DLB group and afterwards in the non-DLB
group (a mean of 0.30 years before in the DLB group and 0.15
years after in the non-DLB group; t =−3.11, P = 0.002). We did
not, however, find a significant difference between the time of
onset of cognitive impairment and initiation of treatment (mean
of 2.4 years for both the DLB and non-DLB groups; t = 0.16, P =
0.87).
We also found that the younger the patient, the longer it took
from first appointment to final diagnosis, in the DLB group
(Pearson’s, R =−0.44, P < 0.001; see Fig. 1) and this was more so
than in the non-DLB group (Pearson’s, R =−0.21, P = 0.08).
Comparison of symptoms in DLB
When the two geographical regions were compared (see Table 3), at
the time of diagnosis, a significantly higher number of core clinical
features,8 but a significantly lower number of suggestive features
were recorded in the participants with DLB in East Anglia compared
with those in the North East. There were also a significantly higher
number of FP-CIT scans (31 compared to 1) carried out in the
North East, and a high proportion of these were abnormal (77%).
Diagnostic threshold in DLB
The majority of participants with DLB (57%, 13/23) in East Anglia
exceeded the threshold for ‘probable’DLB as set out in the 2005 cri-
teria8 (namely more than two core features or one core feature and a
suggestive feature) at the time of final diagnosis, whereas only 35%
(18/51) exceeded this threshold in the North East (see Fig. 2).
Comparison of imaging and comorbidities in DLB
Prior to diagnosis, the DLB group had a similar number of com-
puted tomography (CT) head scans and SPECT perfusion brain
imaging to those in the non-DLB group, but more magnetic reson-
ance imaging (MRI) scans and FP-CIT scans (see Table 4).
The vast majority of patients with dementia of both types were
diagnosed by old age psychiatrists (84% of the DLB group (62/74)
and 93% of the non-DLB group (67/72), with a slightly higher pro-
portion of those in the DLB group than in the non-DLB group diag-
nosed by neurologists (11% v. 3%, 8/74 v. 2/72). The remaining
patients were diagnosed by geriatricians.
The DLB group also experienced significantly higher rates of
repeated falls, urinary incontinence, non-visual hallucinations and
delusions compared with the non-DLB dementia group (see
Table 5).
Dementia symptoms before diagnosis in PDD
Analysis of the case notes for the PDD group revealed that 46% (12/
26 participants with PDD, as for a further 12 participants with PDD
data were missing) had impaired activities of daily living (ADLs)
because of cognitive impairment prior to their diagnosis of demen-
tia. The mean intervening time from ADL impairment being
recorded and dementia diagnosis was 1.5 years. Furthermore, 57%
(16/28 of the PDD group) had cognitive impairment in multiple
domains with a mean onset time period of 2 years prior to dementia
diagnosis. In addition, 38% (6/16 of the PDD group) had both mul-
tidomain cognitive impairment and as a consequence, impaired
ADLs, prior to a diagnosis of dementia, with a mean time of 1.4
years before such dementia diagnosis.
Table 1 Demographics: comparison of gender, age at referral and disease duration for participants
DLB group Non-DLB group
Statistics, DLB versus
non-DLB groups PDD group
Parkinson’s
disease group
Statistics, PDD group
versus Parkinson’s
disease group
t-test χ2-test P t-test χ2-test P
Participants, n 74 72 – N/A N/A 38 35 – N/A N/A
Age, years: mean (s.d.) 77.6 (8.4) 77.2 (8.0) 0.31 0.76 70.7 (7.0) 70.4 (7.2) 0.19 – 0.85
Gender, male/female: n 44/30 42/30 0.19 0.89 28/10 26/9 – 0.003 0.95
MMSE score, mean (s.d.) 21.2 (5.3) 20.3 (4.9) 1.04 0.30
Disease duration, from onset of cognitive
symptoms to final diagnosis (years):
mean (s.d.).
2.9 (2.8) 2.3 (2.6) 1.26 – 0.21 – – – – –
Duration of Parkinson’s disease, from
diagnosis to end of screening period
(years): mean (s.d.).
– – – – – 9.4 (5.7) 6.6 (3.9) −2.3 – 0.024
MMSE, Mini-Mental State Examination.
Table 2 Comparison of the diagnostic pathways for dementia with Lewy bodies (DLB) group versus non-DLB groupa
DLB group,
mean (s.d.) range
Non-DLB group,
mean (s.d.) range Student’s t-test P
Number of diagnoses before final diagnosis 0.8 (0.9) 0–4 0.4 (0.7) 0–3 3.08 0.002
Time between first secondary care appointment and final diagnosis (years) 1.2 (1.8) 0–8 0.6 (1.0) 0–5 2.42 0.017
Number of imaging tests before final diagnosis (including FP-CIT scan) 1.7 (1.0) 0–5 1.2 (0.8) 0–4 3.09 0.002
Number of clinical assessments at home before final diagnosis 3.9 (7.3) 0–40 1.8 (2.5) 0–15 2.31 0.02
Number of clinic appointments before final diagnosis 2.6 (5.7) 0–30 1.5 (2.2) 0–13 1.45 0.15
FP-CIT, 123I-N-ω-fluoropropyl-2beta-carbomethoxy-3beta-4-iodophenyl nortropane brain single-photon emission computerised tomography.
a. How the DLB and non-DLB group reached their final diagnosis was compared, including the number of alternative diagnoses received before their final diagnosis.
Pathways to Lewy body dementia diagnosis
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Fig. 1 Correlation between age of participants with dementia with Lewy bodies (DLB) and time from first appointment to final diagnosis.
Relationship between age, and time from first appointment to final diagnosis, in patients with DLB.
Table 3 Regional differences in dementia with Lewy bodies (DLB) diagnosisa
North East East Anglia t-test χ2-test P
Core features of DLB at time of diagnosis, mean (s.d.) range 1.5 (0.9) 0–3 2.1 (0.9) 0–3 –2.78 – 0.007
Suggestive features of DLB at time of diagnosis, including FP-CIT scan, mean (s.d.) range 0.8 (0.8) 0–2 0.4 (0.5) 0–1 2.63 – 0.011
Abnormal FP-CIT scan prior to diagnosis, n 24 1 – 12.9 0.001
FP-CIT scan prior to diagnosis (including normal), n 31 1 – 20.6 <0.001
Total diagnostic features (core and suggestive) of DLB at time of diagnosis, mean (s.d.) 2.4 (1.0) 2.6 (0.9) −0.80 – 0.42
Time between first secondary care appointment and final diagnosis in years, mean (s.d.) range 1.4 (1.7) 0–7 0.9 (1.9) 0–8 1.03 – 0.31
FP-CIT, 123I-N-ω-fluoropropyl-2beta-carbomethoxy-3beta-4-iodophenyl nortropane brain single-photon emission computerised tomography.
a. Core and suggestive features as set out in the 2005 diagnostic criteria.8
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Fig. 2 Diagnostic threshold in dementia with Lewy bodies (DLB).
Regional differences in diagnostic threshold for DLB diagnosis with respect to clinical features at the time of final diagnosis.
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Treatment before diagnosis in PDD
In total, 39% (9/23) of the PDD group were started on anti-dementia
drugs in the form of rivastigmine or donepezil before a diagnosis of
dementia, with the mean time of starting the treatment before diag-
nosis being 1 year and 9 months.
Participants with symptomatic Parkinson’s disease not
diagnosed with dementia
Patients without a diagnosis of PDD but nevertheless being treated
with anti-dementia medications (such as rivastigmine) within the
screening period had been excluded from being in the Parkinson’s
disease control group. Nevertheless, five of the Parkinson’s disease
control group were found to have received anti-dementia medica-
tions (both initiated and withdrawn) before the onset of the screen-
ing period. One such patient who had received rivastigmine was
noted to have had visual hallucinations, which may have been an
indication for starting that drug as it can be initiated for treatment
of psychosis. None of the other patients on anti-dementia treatment
were recorded to have any other features of psychosis.
In addition, two of the Parkinson’s disease group had cognitive
impairment that affected ADLs and six of patients in this group had
cognitive impairment in multiple domains.
Clinicians making the diagnosis
Where data was available (for 34 in the PDD group and 32 in the
Parkinson’s disease group), old age psychiatrists were found to
have made the dementia diagnoses in 16 patients in the PDD
(47%) group, neurologists in 3 (9%), geriatricians in 13 (38%), a
Parkinson’s disease nurse specialist in 1 (3%) and a general
practitioner in 1 (3%). For the Parkinson’s disease group, the
diagnosis of Parkinson’s disease was made by neurologists in
9 (28%) and geriatricians in 23 (72%) patients.
Symptoms and comorbidities in the PDD group
compared with the Parkinson’s disease group
The PDD group had more visual hallucinations (86% v. 28% (31/36
v. 8/29), χ2 = 22.9, P < 0.001) and cognitive fluctuations (75% v. 11%
(21/28 v. 3/27), χ2 = 22.8, P < 0.001) than the Parkinson’s disease
group. Although rapid eye movement sleep behaviour disorder
was also more common, there was no statistically significant differ-
ence (53% v. 33% (18/34 v. 10/30), χ2 = 2.5, P = 0.12).
Discussion
DLB diagnostic pathway
This study reveals delays in the diagnosis of DLB compared with
non-DLB dementia. Patients with DLB experienced a longer
length of time between their first appointment and receiving a
final diagnosis and had more alternative diagnoses ascribed
within this time. The DLB group also had a higher mean number
of home visits before a final diagnosis and a greater number of
imaging tests. We also found that the lower the age of the partici-
pants with DLB, the longer the time to final diagnosis.
In addition, our results also show that the time to initiation of
anti-dementia drugs after the onset of cognitive symptoms was
not significantly different between the groups. Nevertheless, the
mean time between the date of final diagnosis and initiation of treat-
ment was significantly different, again suggesting difficulty with
identifying dementia subtype rather than dementia itself.
The pathway to diagnosis is hence longer and more challenging
for patients with DLB. The results of this study are consistent with a
retrospective study of caregiver experience of patients with LBD,12
which found two-thirds of patients saw more than three doctors
before an LBD diagnosis was made and a third needed more than
six clinic visits. In addition, in 78% of people a diagnosis of
another disorder was made first. However, that study was entirely
based on caregiver reports with no independent or objective infor-
mation to verify the diagnostic pathway, and also without any com-
parisons with patients with non-LBD. As this was a retrospective
study, it could also have been affected by recall bias, especially
where the experience was mostly negative.
The importance of correctly diagnosing DLB has been high-
lighted in a review13 that identified far-reaching consequences of
having LBD that may not be appreciated without a diagnosis. The
gravest danger being the inadvertent use of anti-psychotics, which
can be fatal in DLB if neuroleptic malignant syndrome is triggered
but can more commonly lead to worsening of their debilitating
movement disorder. The latter may not even be realised by
doctors or patients if it is thought of as progression of dementia.
Patients may also not receive symptomatic treatment for bradykine-
sia or rigidity. Hence a delay in achieving the correct diagnosis could
be severely detrimental to the patient’s care.
Patients with LBD also report lower quality of life than patients
with Alzheimer’s disease, often because of autonomic and neuro-
psychiatric symptoms.14 Higher caregiver stress was also reported
compared with patients with Alzheimer’s disease, in association
with neuropsychiatric symptoms, as well as impaired ADLs.15,16
High levels of caregiver stress have also been identified in LBD as
a whole and this was associated with behavioural problems and
impaired ADLs, together with isolation,17 although that study did
not compare LBD with other dementia subtypes. There is also evi-
dence for a higher mortality risk in DLB than Alzheimer’s disease.13
The timely diagnosis of DLB is therefore important for provid-
ing the necessary clinical care as well as support to the patient and
their caregiver.
Regional variation in DLB diagnosis
We found regional variations in the UK in how DLB was diagnosed,
in particular the thresholds clinicians required for a DLB diagnosis
and also in their use of FP-CIT scans. Clinicians in East Anglia
Table 4 Comparison of imaging between groupsa
DLB group,
mean (s.d.)
Non-DLB group,
mean (s.d.) t-test P
CT, head 0.73 (0.7) 0.81 (0.6) −0.71 0.77
MRI, head 0.32 (0.5) 0.17 (0.4) 2.1 0.04
FP-CIT 0.45 (0.5) 0.03 (0.2) 6.5 <0.001
Perfusion brain SPECT 0.14 (0.3) 0.15 (0.4) −0.29 0.78
DLB, dementia with Lewy bodies; CT, computed tomography; MRI, magnetic resonance
imaging; FP-CIT, 123I-N-ω-fluoropropyl-2beta-carbomethoxy-3beta-4-iodophenyl nortro-
pane brain single-photon emission computerised tomography; SPECT, single-photon
emission computerised tomography.
a. Comparison of the mean number of each brain imaging test per patient, carried out
prior to the final diagnosis in each group.
Table 5 Comparison of non-core features of dementia with Lewy
bodies (DLB) in the DLB and non-DLB groups
DLB
group, % (n)
Non-DLB
group, % (n) χ2-test P
Repeated falls 63.9 (46/72) 34.5 (19/55) 10.7 0.001
Constipation 54.5 (30/55) 39.5 (17/43) 2.2 0.14
Urinary incontinence 64.4 (38/59) 36.8 (14/38) 7.1 0.008
Orthostatic hypotension 44.7 (21/47) 24.1 (7/29) 3.3 0.07
Depression 40.0 (28/70) 39.7 (27/68) <0.1 0.97
Hallucinations (non-visual) 31.3 (21/67) 3.3 (2/61) 17.1 <0.001
Delusions 37.7 (26/69) 6.3 (4/63) 18.4 <0.001
Pathways to Lewy body dementia diagnosis
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appeared to require higher levels of evidence to make a diagnosis of
DLB, whichmay explain the previously reported lower rates of diag-
nosis of DLB in this region compared with the North East (3.3% v.
5.6%).6 Such differences in the diagnostic approach of clinicians
highlights the need for a more standardised approach.
The frequent use of FP-CIT scans in the North East compared
with an almost complete absence of their use in East Anglia (31 v. 1
scans used, respectively), may also partly explain these differences in
diagnostic rates. FP-CIT imaging has been shown using autopsy val-
idation to have high rates of sensitivity (>80%) and specificity
(>90%) for DLB.18,19 An abnormal FP-CIT scan is a suggestive
feature in the 2005 criteria8 and an indicative biomarker in the
updated 2017 criteria.7 The reasons why clinicians in East Anglia
are not utilising this form of imaging is unclear. The benefits of
FP-CIT scans in patients with ‘possible’ DLB has previously been
reported20 – an abnormal scan can increase the likelihood of clini-
cians diagnosing ‘probable’ DLB, as only one additional criterion is
required: a single core feature. Clinicians may have also been more
confident making a diagnosis with an abnormal scan result rather
than purely on clinical grounds. Indeed, seven patients with DLB
were diagnosed based on an abnormal FP-CIT scan and a single
core feature in the North East, whereas there were no individuals
in East Anglia diagnosed based on an abnormal FP-CIT scan and
a single core feature. Hence the infrequent use of FP-CIT scans
may be an important factor in the lower rates of diagnosis of DLB
in East Anglia.
The higher threshold set by clinicians in East Anglia is despite
the excellent specificity of the 2005 diagnostic criteria. A recent
meta-analysis evaluated the 2005 DLB diagnostic criteria for identi-
fying a ‘probable’ DLB diagnosis and reported a sensitivity of 88.3%
and specificity of 80.8%, although there were only three underlying
studies that all focused on later stages (>3 years after onset) of the
disease.21 Nevertheless the high specificity recorded suggests
setting a higher threshold than the 2005 consensus criteria is
unlikely to increase the diagnostic accuracy, but would reduce the
numbers detected, by diminishing the sensitivity.
Together, the delays in achieving the correct diagnosis and the
variations in clinical thresholds set by clinicians for the diagnosis
of DLB could be contributing to the differences in the prevalence
of DLB reported in clinical and pathological studies. These results
also hint at potentially missed cases of people with DLB, if for
example further investigations are not pursued to eventually
rectify an erroneous diagnosis or if clinicians set too high a thresh-
old for diagnosing DLB.
PDD diagnostic pathway
This study also shows that a diagnosis of dementia is often delayed
in patients with Parkinson’s disease. The diagnostic criteria for
PDD9 requires impairment in two cognitive domains plus impair-
ments in ADLs because of cognitive impairment, in the context of
an insidious dementia syndrome. In this study we found that symp-
toms satisfying dementia in Parkinson’s disease were identified in
the medical records by clinicians, yet a diagnosis of dementia was
not made until much later. We also found that many patients
were being treated for dementia before receiving the diagnosis,
again suggesting clinicians were aware such patients had symptoms
consistent with dementia but delayed making a formal diagnosis.
The results of this study also suggest that some patients with
Parkinson’s disease in the control group had features of dementia
in Parkinson’s disease recorded in their clinical notes and may
have even been treated for dementia but were not being diagnosed
as such.
Such a delay in the diagnosis of dementia in Parkinson’s disease
may again lead to a lower rate of diagnosis clinically. The results of
our earlier prevalence study in the same regions found only 9.7% of
patients with Parkinson’s disease had been diagnosed with demen-
tia6 – much lower than a meta-analysis that showed prevalence of
dementia in Parkinson’s disease to be 24.5%.5 A longitudinal
study by Hely and colleagues that observed patients with
Parkinson’s disease over 20 years from diagnosis, found 83% of sur-
vivors developed dementia and 75% of those who had not survived
to 20 years had also developed dementia.22 The study noted neurol-
ogists were more likely to underestimate than overestimate the
prevalence of dementia in patients with Parkinson’s disease, and
recommended that dementia be actively sought and excluded
rather than assumed to be absent.
A delay in the diagnosis of dementia has important implications
for patients and their caregivers. A diagnosis allows for the provi-
sion of support services that they would not otherwise be able to
access. Dementia also leads to loss of insight, poor judgement and
difficulties in financial decision-making, together with impaired
driving skills, among other difficulties,23 which can be considered
and addressed once a diagnosis is formerly made.
Hely and colleagues suggest brief regular assessments through-
out the disease course to detect cognitive decline.22 Instruments
such as an assessment toolkit may aid clinicians in this regard.
For patients with Parkinson’s disease, who typically have regular
follow-ups to assess their movement disorder, this would not
mean an increase in clinic appointments.
PDD symptoms
Visual hallucinations and fluctuating cognition were noted to be
present significantly more in the PDD group (86% and 75%,
respectively) than the Parkinson’s disease control group (28% and
11%), suggesting these clinical features may have been used by clin-
icians as surrogate markers to make a dementia diagnosis – they are
not part of the MDS criteria.9 Both are core features of DLB, which
shares many of the pathological features of PDD,24 hence it is pos-
sible clinicians are making the dementia diagnoses with this in
mind. Visual hallucinations are less frequent in PDD than DLB,
but have been found to be a strong predictor for the onset of demen-
tia.25 In addition, fluctuations in cognition have been reported at a
similar frequency in patients with DLB and those with PDD but
were not found at all in patients with Parkinson’s disease.26
Clinicians making the diagnosis
This study also found that LBDwas diagnosed primarily by psychia-
trists, irrespective of whether the initial referral to specialist services
was to neurology or psychiatry. Although geriatricians and neurol-
ogists made the diagnoses of Parkinson’s disease, a dementia diag-
nosis was made in the main by old age psychiatrists with
geriatricians a close second. Patients with Parkinson’s disease are
regularly followed up by neurologists and geriatricians in the UK.
Both sets of clinicians would be able to make a dementia diagnosis,
but the study results suggest neurologists referred patients with
Parkinson’s disease to psychiatry services for a diagnosis of PDD.
DLB diagnoses were also mainly made by psychiatrists; however,
unlike patients with PDD,most patients with DLBwere seen by psy-
chiatrists initially.
Limitations
The study is a retrospective study that could predispose to recall
bias, however, the data was collected from contemporaneously
writtenmedical records rather than being based on recall by patients
Surendranathan et al
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or clinicians. A further limitation is the lack of demographic data for
those identified in the prevalence survey but not recruited for ana-
lysis, which may affect the generalisability of the results. Another
potential limitation is that the diagnoses of the patients were not
validated by autopsy, which is the gold standard for diagnosis.
Nevertheless, all case report forms were verified by an expert
panel assessing each patient’s case with reference to the relevant
diagnostic criteria.
Implications
This study reveals delays in the diagnosis of both DLB and PDD.
The pathway to diagnosis for patients with DLB is longer and
more complex and some clinicians appear to set a high threshold
for making a diagnosis. In PDD, there appears to be a lag in the diag-
nosis, beyond the onset of symptoms of dementia. Together these
findings may explain why LBD is considerably under-recognised
clinically compared with its frequency in autopsy studies of demen-
tia and suggests many patients with LBD are not receiving an appro-
priate diagnosis and consequently neither the support nor the
treatment that they desperately need.
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